Novo Nordisk

Official Name: Novo Nordisk A/S

Headquarters: Bagsvaerd, Denmark

Founded: December 21, 1923

Employees: 47,792

CEO: Mr. Lars Fruergaard Jorgensen

show_chart OMXC: NOVO.B +0.93%

Market Cap

kr.1.731 Trillion

DKK as of April 1, 2022

US$257.24 Billion

history Market Cap History

Novo Nordisk market capitalization evolution

Evolution of Novo Nordisk A/S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Novo Nordisk A/S

Detailed Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Wikipedia Introduction

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (45%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services specifically diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza. Novo Nordisk employs more than 45,000 people globally, and markets its products in 180 countries. The corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among 100 Best Companies to Work For in 2010 and 72nd in 2014 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights while spin-off company Novozymes was named fourth.

Source: Wikipedia, retrieved on March 31, 2022, 9:02 p.m.

Stocks & Indices

Novo Nordisk A/S has the following listings and related stock indices.


Stock: Bovespa: N1VO34

Stock: NYSE: NVO

Stock: BMV: NVON

Stock: FSX: NOVC



Stock: FSX: NOVA

Product & Services

Ozempic, Ryzodeg, Victoza, NovoEight, Activella, Novolin, Levemir, NovoSeven, Norditropin, Tresiba, Xultophy, NovoRapid, Fiasp, Saxenda

Key People

Helge Lund (Chairman) Lars Fruergaard Jørgensen (President & CEO)


Revenue: DKK 140.80 billion (2021)

Operating income: DKK 52.483 billion (2019)

Net income: DKK 38.951 billion (2019)

Total assets: DKK 125.612 billion (2019)

Total equity: DKK 57.593 billion (2019)



Novo Allé

Bagsvaerd, 2880


Phone: 45 44 44 88 88